CLINICAL_TRIALS
trial_result
· 2024-07-11
Clinical Trial Update: Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma [Phase 2]
Summary
A Phase 2 clinical trial update evaluating the combination of pembrolizumab and lenvatinib for resectable hepatocellular carcinoma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Shanghai Zhongshan Hospital | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: ACTIVE_NOT_RECRUITING